Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAT5906 in Wet Age-related Macular Degeneration
NCT05141994Phase 2Completed
- Sponsor
- Bio-Thera Solutions, Ltd.
- Start
- Aug 2020
- Primary completion
- Sep 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of BAT5906 in exudative macular degeneration (2 arms), sponsored by Bio-Thera Solutions, Ltd. Primary endpoint: Dose-response relationships at week 24. Started Aug 2020; status: completed.
02
Drugs
BAT5906
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on NCT05141994.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141994.